Moreover, lncRNA PCA3 has been approved by FDA for clinical diagnosis of prostate cancer, so it is feasible to seek lncRNA in peripheral blood for diagnosis of HCC [28]. This evidence concerns the gene PCA3 and prostate carcinoma.